National rank
#5
Position in the 2026 British CEO Performance Ranking.
CEO & company research profile · Reviewed 2026-09-13
Pascal Soriot: AstraZeneca
Pascal Soriot ranks #5 in the 2026 British CEO Performance Ranking with a Meridian score of 87.1. This expanded profile shows the operating record, strategic case, risk factors and category scores behind that result.
Meridian score
87.1 / 100
Composite score using the common seven-factor Meridian framework.
Company
AstraZeneca
A nationally significant listed company included in the 2026 research universe.
Leadership tenure
AstraZeneca CEO since October 2012
Tenure is considered when deciding how much operating evidence can reasonably be attributed to the current CEO.
Operating record
2025 performance snapshot
AstraZeneca generated $58.7bn of 2025 revenue, up 9%, reported EPS rose 45%, and the company recorded 16 positive Phase III studies and 16 blockbuster medicines.
Revenue growth, pipeline execution and a broad blockbuster portfolio support one of the strongest long-duration growth records in the FTSE.
Seven-factor score breakdown
| Factor | Weight | Score |
|---|---|---|
| Shareholder performance | 25% | 88 / 100 |
| Revenue & earnings | 20% | 95 / 100 |
| Capital efficiency | 15% | 90 / 100 |
| Strategic execution | 15% | 94 / 100 |
| Innovation & future investment | 10% | 98 / 100 |
| Workforce signal | 10% | 86 / 100 |
| Governance | 5% | 88 / 100 |
Category scores are editorial-data assessments based on the published methodology and available public evidence. They are designed for comparative research, not investment advice.
Strategic assessment
Strategic execution
Use sustained R&D intensity and global commercial scale to compound growth across oncology, biopharma and rare disease.
Capital allocation
Heavy R&D and manufacturing investment are justified by a broad pipeline and high-value global franchises.
Innovation and future investment
Clinical pipeline productivity is the core of the score, with AI increasingly supporting discovery and development rather than replacing scientific execution.
Workforce and operating model
The model depends on retaining world-class scientific, clinical and regulatory talent.
What could change the ranking
Risks and counterweights
Patent cliffs, trial failure, pricing pressure and execution across a very broad pipeline are the main deductions.
Future editions can move the score materially when annual results, acquisitions, capital-allocation decisions, management changes, regulatory events or significant governance developments alter the evidence base.
View the primary or investor source used for this profile.
Meridian uses annual reports, official results, filings and attributable investor disclosures as the primary evidence layer. Comparative scores are versioned and may change as new evidence becomes available.